Dyadic International, Inc. today announced successful top-line results for the Phase 1 clinical trial of its recombinant protein RBD vaccine candidate, DYAI-100. This marks the first-in-human use of a recombinant protein vaccine expressed by Dyadic's C1-cell... READ →
Precision Vaccinations/ November 29th, 2023
Eliminating fake vaccine news with pharmacist, nurse, and physician review.
Nov 29 • 9:25 am CST
Nov 29 • 6:17 am CST
Merck today announced results from STRIDE-3, a Phase 3 clinical trial evaluating V116, the company’s investigational 21-valent pneumococcal conjugate vaccine specifically designed to protect adults. The trial evaluated the immunogenicity, tolerability, and safety of V116 compared... READ →
Nov 29 • 5:24 am CST
China is confronting a wave of respiratory illnesses that have sparked conversations on social media, drawing attention to the pneumonia wave in the fourth week of November 2023, announced GlobalData. On November 30, 2023, Shreyasee Majumder,... READ →
Nov 28 • 6:00 pm CST
Emergent BioSolutions Inc. today announced that the U.S. Biomedical Advanced Research and Development Authority awarded a $75 million option to Emergent's existing contract to acquire the newly licensed anthrax vaccine CYFENDUS™ . The deliveries are expected... READ →
Nov 28 • 5:25 pm CST
CSL and Arcturus Therapeutics today announced that Japan's Ministry of Health, Labor and Welfare (MHLW) approved ARCT-154, a self-amplifying Messenger RNA (sa-mRNA) COVID-19 vaccine for initial vaccination and booster for adults 18 years and older. The... READ →
For more articles, try our search.